3.3. Time to Symptom Resolution
Fever
All of the patients with symptoms present at baseline reported symptoms on day 3 and day 5. At day 10, a significantly higher proportion of the patients receiving probenecid 1000 mg had resolved symptoms versus placebo (68%, [95% CI 46.5–85.1%] vs. 20%, [95% CI 6.8–40.7%]; log-rank Fever was a prominent COVID-19-related symptom, and an exploratory analysis found a statistically significant difference in the change from baseline for the probenecid 1000 mg group versus either the placebo or probenecid 500 mg-dose groups (